Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
20 Jan 2024
20 Jan 2024
Historique:
received:
04
07
2023
accepted:
08
12
2023
medline:
21
1
2024
pubmed:
21
1
2024
entrez:
20
1
2024
Statut:
epublish
Résumé
The immune responses to Novavax's licensed NVX-CoV2373 nanoparticle Spike protein vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus macaques that immunization with Matrix-M
Identifiants
pubmed: 38245545
doi: 10.1038/s41541-024-00806-2
pii: 10.1038/s41541-024-00806-2
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17Subventions
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 101003653
Informations de copyright
© 2024. The Author(s).
Références
Bangaru, S. et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science 370, 1089–1094 (2020).
pubmed: 33082295
pmcid: 7857404
doi: 10.1126/science.abe1502
Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172–1183 (2021).
pubmed: 34192426
doi: 10.1056/NEJMoa2107659
Dunkle, L. M. et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N. Engl. J. Med. 386, 531–543 (2021).
pubmed: 34910859
doi: 10.1056/NEJMoa2116185
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2020).
pubmed: 33378609
doi: 10.1056/NEJMoa2035389
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
pubmed: 33301246
doi: 10.1056/NEJMoa2034577
Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596, 410–416 (2021).
pubmed: 34252919
pmcid: 8761119
doi: 10.1038/s41586-021-03791-x
Verbeke, R., Hogan, M. J., Loré, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993–2005 (2022).
pubmed: 36351374
pmcid: 9641982
doi: 10.1016/j.immuni.2022.10.014
Bergamaschi, C. et al. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 36, 109504 (2021).
pubmed: 34352226
pmcid: 8299183
doi: 10.1016/j.celrep.2021.109504
Cagigi, A. & Loré, K. Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. Vaccines 9, 61 (2021).
pubmed: 33477534
pmcid: 7831080
doi: 10.3390/vaccines9010061
Nkolola, J. P. et al. Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. Vaccine 32, 2109–2116 (2014).
pubmed: 24556505
pmcid: 3980048
doi: 10.1016/j.vaccine.2014.02.001
Bengtsson, K. L. et al. Matrix-M adjuvant enhances antibody, cellular, and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine 34, 1927–1935 (2016).
pubmed: 26921779
doi: 10.1016/j.vaccine.2016.02.033
Ols, S. et al. Route of vaccine administration alters antigen trafficking but not innate or adaptive immunity. Cell Rep. 30, 3964–3971.e7 (2020).
pubmed: 32209459
pmcid: 7198771
doi: 10.1016/j.celrep.2020.02.111
Phad, G. E. et al. Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses. J. Exp. Med. 217, e20191155 (2019).
pmcid: 7041718
doi: 10.1084/jem.20191155
Zhou, F., Hansen, L., Pedersen, G., Grødeland, G. & Cox, R. Matrix M adjuvanted H5N1 vaccine elicits broadly neutralizing antibodies and neuraminidase inhibiting antibodies in humans that correlate with in vivo protection. Front. Immunol. 12, 747774 (2021).
pubmed: 34887855
pmcid: 8650010
doi: 10.3389/fimmu.2021.747774
Magnusson, S. E. et al. Immune enhancing properties of the novel Matrix-M
pubmed: 23384754
doi: 10.1016/j.vaccine.2013.01.039
Datoo, M. S. et al. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years’ follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect. Dis. 22, 1728–1736 (2022).
pubmed: 36087586
doi: 10.1016/S1473-3099(22)00442-X
Guebre-Xabier, M. et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine 38, 7892–7896 (2020).
pubmed: 33139139
pmcid: 7584426
doi: 10.1016/j.vaccine.2020.10.064
Tian, J.-H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372 (2021).
pubmed: 33446655
pmcid: 7809486
doi: 10.1038/s41467-020-20653-8
Keech, C. et al. Phase 1–2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320–2332 (2020).
pubmed: 32877576
doi: 10.1056/NEJMoa2026920
Silva, M. et al. A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. Sci. Immunol. 6, eabf1152 (2021).
pubmed: 34860581
pmcid: 8763571
doi: 10.1126/sciimmunol.abf1152
Reimer, J. M. et al. Matrix-M
pubmed: 22844480
pmcid: 3402407
doi: 10.1371/journal.pone.0041451
Stertman, L. et al. The matrix-M
doi: 10.1080/21645515.2023.2189885
Francica, J. R. et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci. Transl. Med. 13, eabi4547 (2021).
pubmed: 34315825
pmcid: 9266840
doi: 10.1126/scitranslmed.abi4547
Arunachalam, P. S. et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature 594, 253–258 (2021).
pubmed: 33873199
doi: 10.1038/s41586-021-03530-2
Liang, J. G. et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat. Commun. 12, 1346 (2021).
pubmed: 33649323
pmcid: 7921634
doi: 10.1038/s41467-021-21634-1
Mandolesi, M. et al. SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. Cell Rep. Med. 2, 100252 (2021).
pubmed: 33842900
pmcid: 8020888
doi: 10.1016/j.xcrm.2021.100252
Gagne, M. et al. Protection from SARS-CoV-2 delta one year after mRNA-1273 vaccination in rhesus macaques is coincident with anamnestic antibody response in the lung. Cell 185, 113–130.e15 (2021).
pubmed: 34921774
pmcid: 8639396
doi: 10.1016/j.cell.2021.12.002
Arunachalam, P. S. et al. Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine. Sci. Transl. Med. 14, eabq4130 (2022).
pubmed: 35976993
pmcid: 10466502
doi: 10.1126/scitranslmed.abq4130
Milligan, E. C. et al. Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later. Sci. Transl. Med. 15, eadd6383 (2022).
doi: 10.1126/scitranslmed.add6383
Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci. Immunol. 6, eabi6950 (2021).
pubmed: 33858945
pmcid: 8158969
doi: 10.1126/sciimmunol.abi6950
Cagigi, A. et al. Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination. JCI Insight 6, e151463 (2021).
pubmed: 34665783
pmcid: 8663786
doi: 10.1172/jci.insight.151463
Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024–1042.e21 (2020).
pubmed: 32991844
pmcid: 7494283
doi: 10.1016/j.cell.2020.09.037
Greaney, A. J. et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci. Transl. Med. 13, eabi9915 (2021).
pubmed: 34103407
pmcid: 8369496
doi: 10.1126/scitranslmed.abi9915
Schmidt, F. et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 600, 512–516 (2021).
pubmed: 34544114
pmcid: 9241107
doi: 10.1038/s41586-021-04005-0
Greaney, A. J. et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat. Commun. 12, 4196 (2021).
pubmed: 34234131
pmcid: 8263750
doi: 10.1038/s41467-021-24435-8
Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377, eabq0839 (2022).
pubmed: 35857620
doi: 10.1126/science.abq0839
Walls, A. C. et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 184, 5432–5447.e16 (2021).
pubmed: 34619077
pmcid: 8440233
doi: 10.1016/j.cell.2021.09.015
Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix–specific human antibody. Science 373, 1109–1116 (2021).
pubmed: 34344823
pmcid: 9268357
doi: 10.1126/science.abj3321
Zhou, P. et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci. Transl. Med. 14, eabi9215 (2022).
pubmed: 35133175
doi: 10.1126/scitranslmed.abi9215
Dacon, C. et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science 377, 728–735 (2022).
pubmed: 35857439
doi: 10.1126/science.abq3773
Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434–2451.e17 (2022).
pubmed: 35764089
pmcid: 9135677
doi: 10.1016/j.cell.2022.05.022
Kaku, C. I. et al. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination. Science 375, 1041–1047 (2022).
pubmed: 35143256
doi: 10.1126/science.abn2688
Kaku, C. I. et al. Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection. Sci. Immunol. 7, eabq3511 (2022).
pubmed: 35549299
doi: 10.1126/sciimmunol.abq3511
Planchais, C. et al. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. J. Exp. Med. 219, e20220638 (2022).
pubmed: 35704748
pmcid: 9206116
doi: 10.1084/jem.20220638
Gorman, M. J. et al. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M
pubmed: 34485950
pmcid: 8405506
doi: 10.1016/j.xcrm.2021.100405
Kaplonek, P. et al. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity 55, 355–365.e4 (2022).
pubmed: 35090580
pmcid: 8733218
doi: 10.1016/j.immuni.2022.01.001
Schiepers, A. et al. Molecular fate-mapping of serum antibody responses to repeat immunization. Nature 615, 482–489 (2023).
pubmed: 36646114
pmcid: 10023323
doi: 10.1038/s41586-023-05715-3
Tas, J. M. J. et al. Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses. Immunity 55, 1856–1871.e6 (2022).
pubmed: 35987201
pmcid: 9350677
doi: 10.1016/j.immuni.2022.07.020
Liang, F. et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci. Transl. Med. 9, eaal2094 (2017).
pubmed: 28592561
doi: 10.1126/scitranslmed.aal2094
Röltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025–1040.e14 (2022).
pubmed: 35148837
pmcid: 8786601
doi: 10.1016/j.cell.2022.01.018
Lenart, K. et al. A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. Mol. Ther. Methods Clin. Dev. 27, 309–323 (2022).
pubmed: 36217434
pmcid: 9535876
doi: 10.1016/j.omtm.2022.10.001
Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682–687 (2020).
pubmed: 33045718
pmcid: 8092461
doi: 10.1038/s41586-020-2852-1
Corbett, K. S. et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 373, eabj0299 (2021).
pubmed: 34529476
pmcid: 8449013
doi: 10.1126/science.abj0299
Martinez-Murillo, P. et al. Particulate array of well-ordered HIV clade C Env trimers elicits neutralizing antibodies that display a unique V2 cap approach. Immunity 46, 804–817.e7 (2017).
pubmed: 28514687
pmcid: 5528178
doi: 10.1016/j.immuni.2017.04.021
Francica, J. R. et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv. 1, 2329–2342 (2017).
pubmed: 29296883
pmcid: 5729628
doi: 10.1182/bloodadvances.2017011411
Cirelli, K. M. et al. Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. Cell 177, 1153–1171.e28 (2019).
pubmed: 31080066
pmcid: 6619430
doi: 10.1016/j.cell.2019.04.012
Chung, K. Y. et al. ISCOMATRIX
pubmed: 26093202
doi: 10.1016/j.vaccine.2015.06.047
Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet Lond. Engl. 397, 1809–1818 (2021).
doi: 10.1016/S0140-6736(21)00943-0
Bon, A. L. et al. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461–470 (2001).
pubmed: 11336691
doi: 10.1016/S1074-7613(01)00126-1
Thompson, E. A. et al. TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI Insight 3, e120692 (2018).
pubmed: 29769448
pmcid: 6012510
doi: 10.1172/jci.insight.120692
Teijaro, J. R. & Farber, D. L. COVID-19 vaccines: modes of immune activation and future challenges. Nat. Rev. Immunol. 21, 195–197 (2021).
pubmed: 33674759
pmcid: 7934118
doi: 10.1038/s41577-021-00526-x
Bengtsson, K. L., Karlsson, K. H., Magnusson, S. E., Reimer, J. M. & Stertman, L. Matrix-M
doi: 10.1586/14760584.2013.814822
Cibulski, S. P. et al. Quillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses. Sci. Rep. 8, 13582 (2018).
pubmed: 30206376
pmcid: 6134118
doi: 10.1038/s41598-018-31995-1
Fossum, C. et al. Early inflammatory response to the saponin adjuvant Matrix-M in the pig. Vet. Immunol. Immunopathol 158, 53–61 (2014).
pubmed: 23988177
doi: 10.1016/j.vetimm.2013.07.007
Terreri, S. et al. Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. Cell Host Microbe 30, 400–408.e4 (2022).
pubmed: 35134333
pmcid: 8820949
doi: 10.1016/j.chom.2022.01.003
Brewer, R. C. et al. BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2. Nat. Immunol. 23, 33–39 (2021).
pubmed: 34848871
pmcid: 8776031
doi: 10.1038/s41590-021-01088-9
Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2. Cell 184, 3936–3948.e10 (2021).
pubmed: 34192529
pmcid: 8185186
doi: 10.1016/j.cell.2021.06.005
Ladner, J. T. et al. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep. Med. 2, 100189 (2021).
pubmed: 33495758
pmcid: 7816965
doi: 10.1016/j.xcrm.2020.100189
Lin, C.-Y. et al. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. Cell Host Microbe 30, 83–96.e4 (2022).
pubmed: 34965382
doi: 10.1016/j.chom.2021.12.005
Schaefer-Babajew, D. et al. Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. Nature 613, 735–742 (2023).
pubmed: 36473496
doi: 10.1038/s41586-022-05609-w
Inoue, T. et al. Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. J. Exp. Med 220, e20221786 (2022).
pubmed: 36512034
pmcid: 9750191
doi: 10.1084/jem.20221786
Bahnan, W. et al. Spike-dependent opsonization indicates both dose-dependent inhibition of phagocytosis and that non-neutralizing antibodies can confer protection to SARS-CoV-2. Front. Immunol. 12, 808932 (2022).
pubmed: 35095897
pmcid: 8796240
doi: 10.3389/fimmu.2021.808932
Beaudoin-Bussières, G. et al. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Cell Rep. 38, 110368–110368 (2022).
pubmed: 35123652
pmcid: 8786652
doi: 10.1016/j.celrep.2022.110368
Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109–113 (2021).
pubmed: 34182569
pmcid: 8935394
doi: 10.1038/s41586-021-03738-2
Lee, J. H. et al. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature 609, 998–1004 (2022).
pubmed: 36131022
pmcid: 9491273
doi: 10.1038/s41586-022-05216-9
Muecksch, F. et al. Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost. Nature 607, 128–134 (2022).
pubmed: 35447027
pmcid: 9259484
doi: 10.1038/s41586-022-04778-y
Goel, R. R. et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell 185, 1875–1887.e8 (2022).
pubmed: 35523182
pmcid: 8989683
doi: 10.1016/j.cell.2022.04.009
Rodda, L. B. et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell 185, 1588–1601.e14 (2022).
pubmed: 35413241
pmcid: 8926873
doi: 10.1016/j.cell.2022.03.018
Wratil, P. R. et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat. Med. 28, 496–503 (2022).
pubmed: 35090165
doi: 10.1038/s41591-022-01715-4
Lustig, Y. et al. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nat. Immunol. 23, 940–946 (2022).
pubmed: 35534723
doi: 10.1038/s41590-022-01212-3
Jia, J. Z. et al. Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses. Nat. Commun. 13, 6285 (2022).
pubmed: 36271047
pmcid: 9586968
doi: 10.1038/s41467-022-34038-6
Nair, M. S. et al. Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost. iScience 26, 106345 (2023).
pubmed: 36925721
pmcid: 9987605
doi: 10.1016/j.isci.2023.106345
Shinde, V. et al. Improved titers against influenza drift variants with a nanoparticle vaccine. N. Engl. J. Med. 378, 2346–2348 (2018).
pubmed: 29897849
doi: 10.1056/NEJMc1803554
Alves, K. et al. Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373. N. Engl. J. Med. 388, 857–859 (2023).
pubmed: 36734884
doi: 10.1056/NEJMc2215509
Chalkias, S. et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat. Med. 28, 2388–2397 (2022).
pubmed: 36202997
pmcid: 9671805
doi: 10.1038/s41591-022-02031-7
Chalkias, S. et al. A bivalent Omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 387, 1279–1291 (2022).
pubmed: 36112399
doi: 10.1056/NEJMoa2208343
Corbett, K. S. et al. Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine–boosted nonhuman primates. Science 374, 1343–1353 (2021).
pubmed: 34672695
doi: 10.1126/science.abl8912
Gagne, M. et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing antibodies and protection against Omicron. Cell 185, 1556–1571.e18 (2022).
pubmed: 35447072
pmcid: 8947944
doi: 10.1016/j.cell.2022.03.038
Ying, B. et al. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell 185, 1572–1587.e11 (2022).
pubmed: 35452622
pmcid: 8958157
doi: 10.1016/j.cell.2022.03.037
Wang, Q. et al. Antibody response to Omicron BA.4–BA.5 bivalent booster. N. Engl. J. Med. 388, 567–569 (2023).
pubmed: 36630643
doi: 10.1056/NEJMc2213907
Collier, A. Y. et al. Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters. N. Engl. J. Med. 388, 565–567 (2023).
pubmed: 36630611
doi: 10.1056/NEJMc2213948
Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).
pubmed: 35016199
doi: 10.1038/s41586-021-04389-z
Park, Y.-J. et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 378, 619–627 (2022).
pubmed: 36264829
doi: 10.1126/science.adc9127
Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114–119 (2021).
pubmed: 34488225
pmcid: 8566220
doi: 10.1038/s41586-021-03944-y
McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2020).
pubmed: 33276369
pmcid: 7906955
doi: 10.1038/s41586-020-03041-6
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med 27, 1205–1211 (2021).
pubmed: 34002089
doi: 10.1038/s41591-021-01377-8
Israelow, B. et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci. Immunol. 6, eabl4509 (2021).
pubmed: 34623900
pmcid: 9047536
doi: 10.1126/sciimmunol.abl4509
Brasu, N. et al. Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination. Nat. Immunol. 23, 1445–1456 (2022).
pubmed: 36138186
doi: 10.1038/s41590-022-01313-z
Liu, J. et al. CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques. Sci. Immunol. 7, eabq7647 (2022).
pubmed: 35943359
doi: 10.1126/sciimmunol.abq7647
Pavot, V. et al. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. Nat. Commun. 13, 1699 (2022).
pubmed: 35361754
pmcid: 8971430
doi: 10.1038/s41467-022-29219-2
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
pubmed: 32075877
pmcid: 7164637
doi: 10.1126/science.abb2507
Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276–278 (2020).
pubmed: 32055031
doi: 10.1038/s41587-020-0439-x
Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195–204 (2014).
pubmed: 24336226
doi: 10.1038/ni.2789
Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274–1278 (2020).
pubmed: 32404477
pmcid: 7223722
doi: 10.1126/science.abc2241
Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437–442 (2020).
pubmed: 32555388
pmcid: 7442695
doi: 10.1038/s41586-020-2456-9
Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 370, 950–957 (2020).
pubmed: 32972994
pmcid: 7857395
doi: 10.1126/science.abe3354
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
pubmed: 32422645
doi: 10.1038/s41586-020-2349-y
Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633 (2020).
pubmed: 32245784
pmcid: 7164391
doi: 10.1126/science.abb7269
Manenti, A. et al. Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples. J. Med. Virol. 92, 2096–2104 (2020).
pubmed: 32383254
pmcid: 7267461
doi: 10.1002/jmv.25986
Bewley, K. R. et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nat. Protoc. 16, 3114–3140 (2021).
pubmed: 33893470
doi: 10.1038/s41596-021-00536-y
Sheward, D. J. et al. Evasion of neutralising antibodies by omicron sublineage BA.2.75. Lancet Infect. Dis. 22, 1421–1422 (2022).
pubmed: 36058228
pmcid: 9436366
doi: 10.1016/S1473-3099(22)00524-2
Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8–19 (2011).
pubmed: 21192942
doi: 10.1016/j.jim.2010.12.016
Karsten, C. B. et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. J. Immunol. Methods 471, 46–56 (2019).
pubmed: 31132351
pmcid: 6620195
doi: 10.1016/j.jim.2019.05.006
Fischinger, S. et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J. Immunol. Methods 473, 112630 (2019).
pubmed: 31301278
pmcid: 6722412
doi: 10.1016/j.jim.2019.07.002
Lê, S., Josse, J. & Husson, F. FactoMineR: an R package for multivariate analysis. J. Stat. Softw. 25, 1–18 (2008).
doi: 10.18637/jss.v025.i01
Brochu, H. N. et al. Systematic profiling of full-length Ig and TCR repertoire diversity in rhesus macaque through long read transcriptome sequencing. J. Immunol. 204, 3434–3444 (2020).
pubmed: 32376650
pmcid: 7276939
doi: 10.4049/jimmunol.1901256
Sundling, C., Phad, G., Douagi, I., Navis, M. & Hedestam, G. B. K. Isolation of antibody V(D)J sequences from single cell sorted rhesus macaque B cells. J. Immunol. Methods 386, 85–93 (2012).
pubmed: 22989932
doi: 10.1016/j.jim.2012.09.003
Cerveira, R. A. & Ols, S. Scifer: single-cell immunoglobulin filtering of sanger sequences. R package version 1.2.0. https://doi.org/10.18129/b9.bioc.scifer (2023).
Bernat, N. V. et al. Rhesus and cynomolgus macaque immunoglobulin heavy-chain genotyping yields comprehensive databases of germline VDJ alleles. Immunity 54, 355–366.e4 (2021).
doi: 10.1016/j.immuni.2020.12.018
Corcoran, M. M. et al. Production of individualized V gene databases reveals high levels of immunoglobulin genetic diversity. Nat. Commun. 7, 13642 (2016).
pubmed: 27995928
pmcid: 5187446
doi: 10.1038/ncomms13642